ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) for Pleomorphic Sarcoma
This trial is testing whether a new technology is safe and effective for treating a type of cancer.
- Undifferentiated Pleomorphic Sarcoma
2 Primary · 9 Secondary · Reporting Duration: Approximately 1-4 months
3 Treatment Groups
Group 1: Newly diagnosed local Undifferentiated Pleomorphic Sarcoma (UPS)
1 of 3
Group 2: Metastatic UPS
1 of 3
Undifferentiated Pleomorphic Sarcoma (UPS)
1 of 3
20 Total Participants · 3 Treatment Groups
Primary Treatment: ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Could you provide an estimate of how many participants are partaking in this experiment?
"Affirmative. According to the information uploaded on clinicaltrials.gov, this study is recruiting participants and has been since 1/23/2020. The most recent update was made on 9/2/2022, with a goal of enrolling 20 patients from one location." - Anonymous Online Contributor
Does this experiment currently require additional volunteers?
"The information that can be found on clinicaltrials.gov displays this trial is in search of participants. It was originally advertised on January 23rd 2020, with the most recent data update occurring September 2nd 2022." - Anonymous Online Contributor
What goals is this clinical trial attempting to accomplish?
"This medical trial aspires to assess the occurrence of any device-associated adverse events over a period extending from 1 to 4 months. Secondary objectives include calculating percent change in myeloid cell populations, determining presence of immune cells within sarcoma tissue samples and measuring concentrations of cytokines with serological analyses." - Anonymous Online Contributor